WO2008149563A1 - 作用選択的ビタミンｄ受容体作用剤 - Google Patents

作用選択的ビタミンｄ受容体作用剤 Download PDF

Info

Publication number
WO2008149563A1
WO2008149563A1 PCT/JP2008/050027 JP2008050027W WO2008149563A1 WO 2008149563 A1 WO2008149563 A1 WO 2008149563A1 JP 2008050027 W JP2008050027 W JP 2008050027W WO 2008149563 A1 WO2008149563 A1 WO 2008149563A1
Authority
WO
WIPO (PCT)
Prior art keywords
function
receptor agonist
vitamin
selective vitamin
selective
Prior art date
Application number
PCT/JP2008/050027
Other languages
English (en)
French (fr)
Inventor
Makoto Makishima
Michiyasu Ishizawa
Manabu Matsunawa
Sachiko Yamada
Original Assignee
Nihon University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon University filed Critical Nihon University
Priority to JP2009517731A priority Critical patent/JP5283043B2/ja
Priority to US12/601,998 priority patent/US9278992B2/en
Priority to EP08702908.8A priority patent/EP2163557B1/en
Publication of WO2008149563A1 publication Critical patent/WO2008149563A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

　ビタミンD3製剤の副作用である高カルシウム血症を誘導しないVDRリガンドを提供する。　リトコール酸プロピオネート、その塩、その溶媒和物又はそのプロドラッグを含む組成物。
PCT/JP2008/050027 2007-06-04 2008-01-07 作用選択的ビタミンｄ受容体作用剤 WO2008149563A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009517731A JP5283043B2 (ja) 2007-06-04 2008-01-07 作用選択的ビタミンｄ受容体作用剤
US12/601,998 US9278992B2 (en) 2007-06-04 2008-01-07 Function-selective vitamin D receptor agonist
EP08702908.8A EP2163557B1 (en) 2007-06-04 2008-01-07 Function-selective vitamin d receptor agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007147866 2007-06-04
JP2007-147866 2007-06-04

Publications (1)

Publication Number Publication Date
WO2008149563A1 true WO2008149563A1 (ja) 2008-12-11

Family

ID=40093393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050027 WO2008149563A1 (ja) 2007-06-04 2008-01-07 作用選択的ビタミンｄ受容体作用剤

Country Status (4)

Country Link
US (1) US9278992B2 (ja)
EP (1) EP2163557B1 (ja)
JP (1) JP5283043B2 (ja)
WO (1) WO2008149563A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017131144A1 (ja) * 2016-01-28 2017-08-03 国立大学法人お茶の水女子大学 ビタミンｄ活性を有するリトコール酸誘導体
CN114686450A (zh) * 2020-12-28 2022-07-01 苏州引航生物科技有限公司 经修饰的维生素d羟化酶突变体及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356006B (es) * 2013-10-18 2018-04-24 Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
CN112074274B (zh) 2018-03-19 2024-03-26 艾匹赛特制药公司 用于治疗因缺钙引起的病状的组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007147866A (ja) 2005-11-25 2007-06-14 Sony Corp 自発光表示装置、発光条件制御装置、発光条件制御方法及びプログラム

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846411A (en) * 1971-08-04 1974-11-05 Medichemie Ag Choleretically active esters and salts of bile acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007147866A (ja) 2005-11-25 2007-06-14 Sony Corp 自発光表示装置、発光条件制御装置、発光条件制御方法及びプログラム

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADACHI, R. ET AL.: "Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative", JOURNAL OF LIPID RESEARCH, vol. 46, 2005, pages 46 - 57, XP008116081 *
ISHIZAWA, M. ET AL.: "Lithocholic acid derivatives act as selective vitamin D receptor modulators", J LIPID RES, 7 January 2008 (2008-01-07), XP008116082, Retrieved from the Internet <URL:http://www.jlr.org/cgi/ reprint/M700293-J> [retrieved on 20080311] *
MAKISHIMA, M. ET AL.: "Vitamin D Receptor As an Intestinal Bile Acid Sensor", SCIENCE, vol. 296, 17 May 2002 (2002-05-17), pages 1313 - 1316, XP008116080 *
NAGPAL, S. ET AL.: "Noncalcemic actions of vitamin D receptor ligands", ENDOCRINE REVIEWS, vol. 26, no. 5, 2005, pages 662 - 687, XP003020911 *
See also references of EP2163557A4 *
SHAIKH ET AL.: "Synthesis and mesomorphic behaviour of lithocholic acid derivatives", BULLETIN OF MATERIAL SCIENCE, vol. 26, no. 5, 2003, pages 559 - 563, XP008116077 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017131144A1 (ja) * 2016-01-28 2017-08-03 国立大学法人お茶の水女子大学 ビタミンｄ活性を有するリトコール酸誘導体
CN114686450A (zh) * 2020-12-28 2022-07-01 苏州引航生物科技有限公司 经修饰的维生素d羟化酶突变体及其应用
CN114686450B (zh) * 2020-12-28 2024-04-16 苏州引航生物科技有限公司 经修饰的维生素d羟化酶突变体及其应用

Also Published As

Publication number Publication date
EP2163557B1 (en) 2014-10-15
JP5283043B2 (ja) 2013-09-04
US9278992B2 (en) 2016-03-08
EP2163557A1 (en) 2010-03-17
EP2163557A4 (en) 2011-06-22
US20100204191A1 (en) 2010-08-12
JPWO2008149563A1 (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
WO2009057104A3 (en) Polymer-based fire-retarding formulations
WO2011163206A3 (en) Controlled release compositions with reduced food effect
ZA200908019B (en) Controlled release pharmaceutical compositions for prolonged effect
EP3413885A4 (en) COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
PT2004636E (pt) Compostos de enaminocarbonilo substituídos utilizados como insecticidas
PL2068822T3 (pl) Wodne kompozycje farmaceutyczne o właściwościach samokonserwujących
HK1138779A1 (en) Oil-in-water type emulsion composition
WO2010036407A3 (en) Antiviral nucleoside analogs
IL213583A0 (en) Solid compositions containing the ingredient rasagiline
WO2010138598A3 (en) Lxr modulators
IL194917A0 (en) Co-extruded compositions for high aspect ratio structures
HK1141986A1 (en) Emulsion compositions
EP2416806B8 (en) Fucoidans as ligands for the diagnosis of degenerative pathologies
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
GB0800991D0 (en) Emulsion for use as confectionery filling
IL194800A0 (en) Pre-mixed, ready-to-use pharmaceutical compositions
WO2012106665A3 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
IL197885A (en) The stabilized prostaglandin compound
WO2014159794A3 (en) Bicyclo [2.2.1] acid gpr120 modulators
WO2008149563A1 (ja) 作用選択的ビタミンｄ受容体作用剤
EP2262536A4 (en) STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS
IL173791A0 (en) Improved stabilization for flight platforms
EG25948A (en) Dust composition for combating insects
EP2170049A4 (en) COMPOUNDS AND COMPOSITIONS FOR PEST CONTROL
WO2012080176A3 (en) Pharmaceutical compositions comprising alisporivir

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08702908

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009517731

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008702908

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12601998

Country of ref document: US